Cardiovascular (CV) diseases continue to be the leading cause of morbidity and mortality worldwide. Significant progress has been made in the management of coronary artery disease (CAD) and acute coronary syndrome (ACS) over the past 3 decades. The year 2017 marks 40th anniversary of the first coronary angioplasty performed by Andreas Gruentzig in the year 1977. Evidence-based medicine and research has been the key driving force of these positive outcomes. The year 2017 witnessed presentation of several landmark studies at major meetings and many of them getting published in literature simultaneously. These trials evaluated wide range of issues from novel percutaneous coronary intervention (PCI) strategies to newer drugs to innovative devices in management of CAD. We selectively discuss a few major landmark studies that have the potential to alter our daily practice in 2018.
Keywords: STEMI; cardiogenic shock; dual antiplatelet; evolocumab; fractional flow reserve (FFR); multivessel disease; rivaroxaban.